Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Saved in:
| Title: | Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. |
|---|---|
| Authors: | Jifang Gong1, Tianshu Liu2, Qingxia Fan3, Li Bai4, Feng Bi5, Shukui Qin6, Jinwan Wang7, Nong Xu8, Ying Cheng9, Yuxian Bai10, Wei Liu11, Liwei Wang12, Lin Shen1 lin100@medmail.com.cn, Gong, Jifang13 (AUTHOR), Liu, Tianshu2 (AUTHOR), Fan, Qingxia3 (AUTHOR), Bai, Li4 (AUTHOR), Bi, Feng5 (AUTHOR), Qin, Shukui6 (AUTHOR), Wang, Jinwan14 (AUTHOR) |
| Source: | BMC Cancer. 2/8/2016, Vol. 16, p1-9. 9p. 1 Diagram, 2 Charts, 2 Graphs. |
| Database: | Academic Search Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 112920378 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Jifang+Gong%22">Jifang Gong</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Tianshu+Liu%22">Tianshu Liu</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Qingxia+Fan%22">Qingxia Fan</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Li+Bai%22">Li Bai</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Feng+Bi%22">Feng Bi</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Shukui+Qin%22">Shukui Qin</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Jinwan+Wang%22">Jinwan Wang</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Nong+Xu%22">Nong Xu</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Ying+Cheng%22">Ying Cheng</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Yuxian+Bai%22">Yuxian Bai</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Wei+Liu%22">Wei Liu</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Liwei+Wang%22">Liwei Wang</searchLink><relatesTo>12</relatesTo><br /><searchLink fieldCode="AR" term="%22Lin+Shen%22">Lin Shen</searchLink><relatesTo>1</relatesTo><i> lin100@medmail.com.cn</i><br /><searchLink fieldCode="AR" term="%22Gong%2C+Jifang%22">Gong, Jifang</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+Tianshu%22">Liu, Tianshu</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fan%2C+Qingxia%22">Fan, Qingxia</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bai%2C+Li%22">Bai, Li</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bi%2C+Feng%22">Bi, Feng</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Qin%2C+Shukui%22">Qin, Shukui</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Jinwan%22">Wang, Jinwan</searchLink><relatesTo>14</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22BMC+Cancer%22">BMC Cancer</searchLink>. 2/8/2016, Vol. 16, p1-9. 9p. 1 Diagram, 2 Charts, 2 Graphs. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=112920378 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12885-016-2092-9 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 9 StartPage: 1 Titles: – TitleFull: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Jifang Gong – PersonEntity: Name: NameFull: Tianshu Liu – PersonEntity: Name: NameFull: Qingxia Fan – PersonEntity: Name: NameFull: Li Bai – PersonEntity: Name: NameFull: Feng Bi – PersonEntity: Name: NameFull: Shukui Qin – PersonEntity: Name: NameFull: Jinwan Wang – PersonEntity: Name: NameFull: Nong Xu – PersonEntity: Name: NameFull: Ying Cheng – PersonEntity: Name: NameFull: Yuxian Bai – PersonEntity: Name: NameFull: Wei Liu – PersonEntity: Name: NameFull: Liwei Wang – PersonEntity: Name: NameFull: Lin Shen – PersonEntity: Name: NameFull: Gong, Jifang – PersonEntity: Name: NameFull: Liu, Tianshu – PersonEntity: Name: NameFull: Fan, Qingxia – PersonEntity: Name: NameFull: Bai, Li – PersonEntity: Name: NameFull: Bi, Feng – PersonEntity: Name: NameFull: Qin, Shukui – PersonEntity: Name: NameFull: Wang, Jinwan IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 02 Text: 2/8/2016 Type: published Y: 2016 Identifiers: – Type: issn-print Value: 14712407 Numbering: – Type: volume Value: 16 Titles: – TitleFull: BMC Cancer Type: main |
| ResultId | 1 |
